In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New AdvaMed Chair Lobo: Devices Has A Good Story To Tell

Nadim Yared Will Be A Hard Act To Follow For New AdvaMed Chair Kevin Lobo

Executive Summary

A whirlwind two-year stint as chair of the US medtech industry association, AdvaMed, came to end this month for CVRx’e energetic CEO Nadim Yared. Incoming chair, Stryker’s Kevin Lobo, comes from an altogether much larger concern, but he will continue Yared’s legacy of supporting SMEs, as well as bringing his own agenda to the role.

You may also be interested in...



After AdvaMed, Yared Takes Helm Of MDIC Board

CVRx CEO Nadim Yared has moved up on the board of directors at the Medical Device Innovation Consortium as its new chair. The public-private partnership group that formed in 2012 has been effective in working with the US Food and Drug Administration to develop new regulations.

UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit

Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.

UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment

Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel